




RealRate

PHARMACEUTICAL 2020

Merrimack Pharmaceuticals INC
Rank 132 of 363



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2020

Merrimack Pharmaceuticals INC Rank 132 of 363

The relative strengths and weaknesses of Merrimack Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merrimack Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Merrimack Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 288%, being 50% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	18,692
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,770
Liabilities, Non-Current	0
Other Assets	1,390
Other Compr. Net Income	9.0
Other Expenses	-6,383
Other Liabilities	0
Other Net Income	3,554
Other Revenues	0
Property and Equipment	0
Research and Development	11,100
Selling, General and Administrative Expense	16,169

Output Variable	Value in 1000 USD
Assets	20,082
Liabilities	2,770
Expenses	20,886
Revenues	0
Stockholders Equity	17,312
Net Income	-17,332
Comprehensive Net Income	-17,328
BaseVar	23,650
ECR before LimitedLiability	179%
Economic Capital Ratio	288%